Literature DB >> 19031164

Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy.

Umberto Ricardi1, Andrea Riccardo Filippi, Alessia Guarneri, Francesca Romana Giglioli, Cristina Mantovani, Christian Fiandra, Silvia Anglesio, Riccardo Ragona.   

Abstract

MATERIALS AND METHODS: The aim was to retrospectively investigate correlations between potential predictive parameters and the occurrence of radiation-induced lung injury in patients with primary or secondary lung tumours treated with stereotactic body radiation therapy (SBRT). Sixty patients (63 tumours) underwent SBRT, with a dose of 45 Gy in 3 fractions over 5 days or 26 Gy in single fraction. The following parameters were tested for correlation with Radiation Therapy Oncology Group (RTOG) lung toxicity score: planning target volume (PTV), tumour location, primary vs. metastatic tumour, and Mean Lung Dose (in 2 Gy fractions, MLD2). Normal Tissue Complication Probability (NTCP) values were then estimated.
RESULTS: The median follow-up time was 30.9 months (range 6.7-56.7). RTOG grade 0-1 toxicity was observed in 54/63 (85.7%) and grade 2-3 in 9/63 (14.3%) cases. Mean values of MLD(2) for RTOG grade 0-1 and 2-3 were respectively 11.2 Gy (95% Confidence Interval (CI) 10.1-12.3 Gy) and 20.3 Gy (95% CI 16.6-23.9 Gy). NTCP mean values for RTOG grade 0-1 and 2-3 were respectively 4% (95% CI 2-5.9%) and 37% (95% CI 11.6-62.3%). Univariate analysis, performed with t-Student test, showed a statistically significant difference between MLD(2) values in the two groups (t=5.93 and p < or = 0.001). Logistic regression analysis showed a good correlation between MLD(2) and toxicity scores 2-3 (p=0.008, odds ratio 1.5). From logistic regression relationship between the observed rates of grade 2-3 and MLD(2), a D(50)=19.8 Gy and a gamma50= 2.2 were obtained. From the sigmoid-shaped dose-response relationship between NTCP and MLD(2), a D(50)=22.4 Gy and gamma(50)= 2.2 were derived. DISCUSSION: MLD(2) is strongly associated to the risk of lung injury. Higher NTCP values are associated with a higher risk, but when comparing the expected to the observed toxicity rate, NTCP seems to underestimate the risk.

Entities:  

Mesh:

Year:  2009        PMID: 19031164     DOI: 10.1080/02841860802520821

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  23 in total

1.  Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer.

Authors:  Arya Amini; Katherine Ciura; James Welsh; Ngoc Nguyen; Matt Palmer; Pamela K Allen; Michael Paolini; Zhongxing Liao; Jaques Bluett; Radhe Mohan; Daniel Gomez; James D Cox; Ritsuko Komaki; Joe Y Chang
Journal:  Med Dosim       Date:  2013       Impact factor: 1.482

Review 2.  Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies.

Authors:  Jing Zhao; Ellen D Yorke; Ling Li; Brian D Kavanagh; X Allen Li; Shiva Das; Moyed Miften; Andreas Rimner; Jeffrey Campbell; Jinyu Xue; Andrew Jackson; Jimm Grimm; Michael T Milano; Feng-Ming Spring Kong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-03-25       Impact factor: 7.038

3.  Dosimetric evaluation of abdominal compression as a method to reduce the incidence of radiation-induced pneumonitis in lung SBRT treatment.

Authors:  Vikren Sarkar; Long Huang; Yu-Huei Jessica Huang; Martin W Szegedi; Prema Rassiah-Szegedi; Hui Zhao; Ying J Hitchcock; Kristine E Kokeny; Brian Wang; Bill J Salter
Journal:  J Radiosurg SBRT       Date:  2016

Review 4.  Radiation pneumonitis after stereotactic radiation therapy for lung cancer.

Authors:  Hideomi Yamashita; Wataru Takahashi; Akihiro Haga; Keiichi Nakagawa
Journal:  World J Radiol       Date:  2014-09-28

5.  Risk factors for radiation pneumonitis after stereotactic radiation therapy for lung tumours: clinical usefulness of the planning target volume to total lung volume ratio.

Authors:  Tomoko Ueyama; Takeshi Arimura; Koji Takumi; Fumihiko Nakamura; Ryutaro Higashi; Soichiro Ito; Yoshihiko Fukukura; Tomokazu Umanodan; Masanori Nakajo; Chihaya Koriyama; Takashi Yoshiura
Journal:  Br J Radiol       Date:  2018-04-16       Impact factor: 3.039

6.  No differences in radiological changes after 3D conformal vs VMAT-based stereotactic radiotherapy for early stage non-small cell lung cancer.

Authors:  Serena Badellino; Jacopo Di Muzio; Giulia Schivazappa; Alessia Guarneri; Riccardo Ragona; Sara Bartoncini; Elisabetta Trino; Andrea Riccardo Filippi; Paolo Fonio; Umberto Ricardi
Journal:  Br J Radiol       Date:  2017-09-04       Impact factor: 3.039

7.  Comparison of clinical, tumour-related and dosimetric factors in grade 0-1, grade 2 and grade 3 radiation pneumonitis after stereotactic body radiotherapy for lung tumours.

Authors:  A Takeda; T Ohashi; E Kunieda; N Sanuki; T Enomoto; T Takeda; Y Oku; N Shigematsu
Journal:  Br J Radiol       Date:  2012-01-17       Impact factor: 3.039

8.  Hypo-fractionated stereotactic radiation therapy for lung malignancies by means of helical tomotherapy: report of feasibility by a single-center experience.

Authors:  Vanessa Figlia; Rosario Mazzola; Francesco Cuccia; Filippo Alongi; Gianluca Mortellaro; Daniela Cespuglio; Teresa Cucchiara; Giuseppina Iacoviello; Vito Valenti; Massimo Molino; Francesco Verderame; Domenica Matranga; Antonio Lo Casto; Giuseppe Ferrera
Journal:  Radiol Med       Date:  2018-02-17       Impact factor: 3.469

9.  Lung stereotactic ablative radiotherapy (SABR): dosimetric considerations for chest wall toxicity.

Authors:  Louise Murray; Ebru Karakaya; Samantha Hinsley; Mitchell Naisbitt; John Lilley; Michael Snee; Katy Clarke; Hima B Musunuru; Satiavani Ramasamy; Rob Turner; Kevin Franks
Journal:  Br J Radiol       Date:  2016       Impact factor: 3.039

10.  Complication probability for radiation pneumonitis (RP) after stereotactic body radiotherapy (SBRT).

Authors:  Jimm Grimm; David Palma; Suresh Senan; Jinyu Xue
Journal:  J Radiosurg SBRT       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.